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Conclusions. The etiology of HCAP was identified in only 
one quarter of patients, with S. pneumoniae being the most 
prevalent microorganism. Patients with chronic respiratory 
diseases more frequently presented HCAP due to MRSA than 
to S. pneumoniae. Death at hospital discharge was related in 
most cases to pneumonia. 
Keywords: Healthcare-associated pneumonia; S. pneumoniae; methicillin 
resistant- Staphylococcus aureus.
Neumonía asociada a cuidados sanitarios: un 
estudio prospectivo en España
RESUMEN
Objetivo. Describir las características epidemiológicas y 
factores relacionados con la neumonía asociada a cuidados 
sanitarios (NACS) causada por Streptococcus pneumoniae y 
Staphylococcus aureus resistente a meticilina (SARM). 
Pacientes y métodos. Estudio epidemiológico observa-
cional prospectivo de casos a 3 años en siete hospitales es-
pañoles. Se recogieron las características microbiológicas y de 
los pacientes y sus resultados y se clasificaron en función del 
patógeno causante en 4 categorías: “S. pneumoniae”, “SARM”, 
“Otros” y “Desconocido”. Al alta, se realizó un seguimiento de 
30 días. 
Resultados. Se incluyeron 258 (84,6%) pacientes (170 
hombres [65.9%]; edad media 72,4 años ± 15 años (95% IC 
[70,54-74,25]). La etiología de la neumonía se identificó en 73 
casos (28,3%): S. pneumoniae en 35 pacientes (13,6%), SARM 
en 8 (3,1%) y otros microorganismos en 30 pacientes (11,6%). 
Hubo diferencias significativas en tasas de enfermedad pul-
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ABSTRACT 
Objective. The aim of the study was to describe the epidemi-
ological characteristics and factors related to outcome in Strep-
tococcus pneumoniae and methicillin-resistant Staphylococcus 
aureus (MRSA) healthcare-associated pneumonia (HCAP). 
Patients and method.: A 3-year prospective observation-
al epidemiological case study of HCAP was conducted in seven 
Spanish hospitals. Microbiological and patient characteristics 
and outcomes were collected and classified by causative path-
ogen into 4 categories: “S. pneumoniae”, “MRSA”, “Others” and 
“Unknown”. Patients were followed up 30 days after discharge. 
Results. A total of 258 (84.6%) patients were enrolled 
(170 were men [65.9%]). Mean age was 72.4 years ± 15 years 
(95% CI [70.54-74.25]). The etiology of pneumonia was identi-
fied in 73 cases (28.3%): S. pneumoniae in 35 patients (13.6%), 
MRSA in 8 (3.1%), and other microorganisms in 30 patients 
(11.6%). Significant differences in rates of chronic obstructive 
pulmonary disease (p < 0.05), previous antibiotic treatment (p 
< 0.05), other chronic respiratory diseases, inhaled corticos-
teroids (p < 0.01), and lymphoma (p < 0.05) were observed 
among the four groups. Patients with MRSA pneumonia had 
received more previous antibiotic treatment (87.5%). Thir-
ty-three (12.8%) patients died during hospitalisation; death in 
27 (81.2%) was related to pneumonia. 
Correspondence:
Dr. María Carmen Fariñas.
Infectious Diseases Unit, Hospital Universitario Marqués de Valdecilla, 
Av. Valdecilla, 25, 39008 Santander, Cantabria, Spain. 
Phone: +34 942202663 
E-mail: mcfarinas@humv.es
*Both authors contributed equally to this manuscript
Healthcare-associated pneumonia: a prospective study in SpainF. Arnaíz de las Revillas, et al.
Rev Esp Quimioter 2020;33(5): 358-368 359
ducted between October 2013 and August 2016 in seven hos-
pitals in Spain.
The study was performed in accordance with the Decla-
ration of Helsinki, the protocol was reviewed and approved by 
the Institutional Ethics Committee of Cantabria (Spain) (refer-
ence 24/2013) and at all participating hospitals, according to 
local standards, and informed consent was obtained from each 
patient. The study was non-interventional, and patients were 
managed according to the criteria of their treating physicians. 
Patients and definitions. Patients ≥ 18 years of age admit-
ted with HCAP with new infiltrates on a chest X-ray and hos-
pitalised at least for 24h in any of the participating hospitals 
were evaluated. Criteria for bloodstream infection described 
elsewhere were followed for patient classification [9]. Inclusion 
criteria were: hospitalisation in an acute care facility for ≥ 2 
days within 90 days before the infection; residence in a nursing 
home or long-term-care facility; intravenous antibiotic ther-
apy, chemotherapy, or wound care, within 30 days before the 
infection; or regular hospital visits or haemodialysis [3].
In addition, for inclusion in the study, a sample of blood 
or normally sterile fluid (pleural fluid, cerebrospinal fluid or 
peritoneal fluid) with or without a corresponding respiratory 
sample was required (obtained before antibiotic treatment or 
in the first 24h after starting antibiotic treatment).
Pneumonia was classified into two categories, complicat-
ed or non-complicated, depending on clinical presentation. 
Complicated pneumonia was defined by the presence of lung 
parenchymal infiltrates and pleural effusions of any size or 
character on chest X-ray or computed tomography, and body 
temperature > 38°C [21]. 
Treatment failure was defined as persistence or progres-
sion of clinical symptoms/signs of pneumonia after two days 
of treatment, or progression of chest X-ray anomalies, or the 
development of new pulmonary or extra-pulmonary clinical 
symptoms/signs of pneumonia consistent with an active infec-
tion.
Microbiological evaluation. Normally sterile fluids (pleural 
fluid, cerebrospinal fluid or peritoneal fluid), nasopharyngeal 
swabs and blood were cultured. S. pneumoniae and MRSA iso-
lates were tested for antibiotic susceptibility by microdilution 
according to Clinical and Laboratory Standards Institute (CLSI) 
recommendations [22]. Furthermore, all nasopharyngeal swabs 
were subjected to real time PCR, targeting lytA for the detec-
tion of S. pneumoniae [23]. Pneumococcal urinary antigen was 
detected using the BinaxNOW kit without concentration (Binax 
Inc., Portland, ME, USA). 
Data collection and follow-up. The following patient data 
were collected: sex, age, place of residence, admission and dis-
charge date if applicable, epidemiological and medical condi-
tions, microbiological study results, history of vaccination, and 
outcomes. The Charlson Comorbidity Index (CCI) score was 
calculated to assess comorbidity [24] and CURB-65 and PORT 
Severity Index (PSI) scores were calculated to stratify patients 
according to risk of mortality [25, 26]. 
monar obstructiva crónica (p < 0,05), tratamiento antibiótico 
previo (p < 0,05), otras enfermedades respiratorias crónicas, 
corticoides inhalados (p < 0,01) y linfoma (p < 0,05) entre los 
cuatro grupos. Los pacientes con NACS causada por SARM 
recibieron tratamiento antibiótico previo en mayor medida 
(87,5%). Treinta y tres (12,8%) pacientes murieron durante la 
hospitalización; en 27 (81,2%) debido a la neumonía. 
Conclusiones. Se identificó la etiología de la NACS en 
solo un cuarto de los pacientes, siendo S. pneumoniae el pa-
tógeno más frecuente. En los pacientes con enfermedades 
respiratorias crónicas fue más frecuente la NACS causada por 
SARM. La muerte tras el alta hospitalaria se relacionó con la 
neumonía en la mayoría de los casos. 
Palabras clave: neumonía asociada a cuidados sanitarios; S. pneumoniae; 
Staphylococcus aureus resistente a meticilina.
INTRODUCTION
Pneumonia has traditionally been classified as either com-
munity-acquired (CAP) or hospital-acquired pneumonia (HAP), 
with both entities being characterised by different microbiologi-
cal profiles [1]. However, over the years, this classification has 
become less clear, leading in 2005 to the appearance of a new 
category called healthcare-associated pneumonia (HCAP). HCAP 
is used to define pneumonia that develops in non-hospitalised 
patients who are in frequent contact with the healthcare en-
vironment and who appear to be at increased risk of infection 
with multi-drug resistant (MDR) pathogens [2, 3] and a poorer 
outcome than patients with CAP [2, 4-6]. As a result, a different 
approach is required when selecting empiric antibiotic therapy 
in these cases [2, 3, 7-10]. However, it is important to bear in 
mind that the concept of HCAP has been the subject of debate 
in recent years, and that several studies have recently ques-
tioned our capacity to identify resistant pathogens [11-14]. 
One of the challenges in the correct management of pa-
tients with pneumonia is achieving an accurate microbiological 
diagnosis. Despite the availability of several tests, the etiolog-
ic agent remains unidentified in at least 50% of CAP cases [15, 
16]. Globally, Streptococcus pneumoniae is the most frequently 
identified etiologic agent in both CAP and HCAP patients [17, 
18], including in Spain [6, 19]. Importantly, methicillin-resistant 
Staphylococcus aureus (MRSA) has also been identified as an 
important causative agent in pneumonia, especially HCAP. Al-
though its incidence is variable in America and Europe, recent 
studies conducted in Italy and Spain have identified MRSA as a 
causative agent in 7%-12.3% of cases [7, 20].
Since an accurate diagnosis is not always possible, we 
conducted a prospective observational epidemiological study 
in seven hospitals from different locations across Spain to de-
scribe the epidemiological characteristics and factors related 
to outcome in S. pneumoniae and MRSA HCAP. 
PATIENTS AND METHODS
Study design. A multicentre prospective study was con-
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terquartile range (IQR). Chi-squared (χ²) and Fisher exact test 
or likelihood ratio were used for categorical variables, and the 
2-tailed t test or Mann-Whitney test for continuous variables, 
as appropriate. Statistical significance was set at α = 0.05. 
RESULTS
Between October 2013 and September 2016, 305 patients 
in seven Spanish hospitals were considered for inclusion in the 
study (Figure 1). Of these, 47 (15.4%) were ineligible because 
they did not meet any of the inclusion criteria. A total of 258 
(84.6%) subjects were finally enrolled and subsequently ana-
lysed; 170 were men (65.9%). Patient distribution according to 
hospital of origin was as follows: 74 (23.7%) from hospital 1; 
78 (30.2%) from hospital 2; 24 (9.3%) from hospital 3; 18 (7%) 
from hospital 4; 36 (14%) from hospital 5; 19 (7.4%) from hos-
pital 6, and 9 (3.5%) from hospital 7. Mean age overall was 
72.4 years (SD: 15 years) (95% CI [70.54-74.25]) and there 
were no age differences between HCAP patients colonised or 
infected with S. pneumoniae (72.6 years; SD = 11.6) or MRSA 
(70.6 years; SD = 17.0). 
Follow-up was performed in outpatient clinics or by tele-
phone thirty days after discharge, and included requirement 
of a new hospitalisation, whether related or not to the HCAP 
episode, and mortality, whether related or not to pneumonia. 
Data were analysed in two different ways. An initial anal-
ysis was conducted according to the presence or absence of 
S. pneumoniae or MRSA, since S. pneumoniae colonisation is 
considered a pre-requisite for pneumococcal infections [27] 
and several studies have confirmed that MRSA nasal colonisa-
tion is a risk factor for subsequent infection [28]. To maximise 
results, all samples that were positive for either colonisation 
or infection were included. A second analysis according to the 
causative agent identified in each of the participating centres’ 
laboratories was performed, and results were classified into 
four different categories: “S. pneumoniae”, “MRSA”, “Others” 
and “Unknown”. 
Statistical analysis. The results were analysed using a com-
mercially available statistical software package (SPSS, version 
17.0; SPSS Inc., Chicago, Illinois, USA). Data were expressed as 
mean value ± standard deviation (SD) or median value and in-
Figura 1  Flow chart representing study methodology.
305 patients included
47 excluded
(Not meeting the inclusion criteria)
258 eligible patients
74 patients from Hospital 1
78 patients from Hospital 2
24 patients from hospital 3
18 patients from hospital 4
36 patients from hospital 5
19 patients from hospital 6
9 patients from hospital 7
33 exitus 225 patients
At hospital discharge
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Age, mean ± SD 71.22 ± 13.99 72.78 ± 15.52 0.218 75.3 ± 15.92 72.01 ± 15.04 0.276
Sex, n (%)
    Male 42 (65.6) 128 (66)
0.959
20 (66.7) 150 (65.8)
0.924
    Female 22 (34.4) 66 (34) 10 (33.3) 78 (34.2)
Relevant history, n (%)
        Hospitalisation (previous 2 months) 29 (45.3) 96 (45.9) 0.563 16 (53.3) 109 (47.8) 0.569
        Malignancy 25 (39.1) 68 (35.1) 0.562 5 (16.7) 88 (38.6) 0.019
        COPD 19 (29.7) 60 (30.9) 0.852 16 (53.3) 63 (27.6) 0.004
        Previous pneumonia 21 (32.8) 55 (28.4) 0.497 13 (43.3) 63 (27.6) 0.076
        Diabetes 17 (26.6) 54 (27.8) 0.843 7 (23.3) 64 (28.1) 0.585
        Institutionalised patients 22 (34.4) 48 (24.7) 0.133 15 (50) 55 (24.1) 0.003
        Heart failure 13 (23.3) 52 (26.8) 0.300 11 (36.7) 54 (23.7) 0.124
    Previous antibiotic treatment 38 (59.4) 106 (54.6) 0.508 21 (70) 123 (53.9) 0.096
    Previous chemotherapy (in the last 30 days) 14 (21.9) 32 (16.5) 0.330 1 (3.3) 45 (19.7) 0.027
Antibiotic treatment
(7 days prior to hospital admission):
    Yes 17 (44.7) 52 (49.1)
0.647
9 (42.9) 60 (48.8)
0.616
    No 21 (55.3) 54 (50.9) 12 (57.1) 63 (51.2)
    With penicillin 6 (35.3) 9 (17.3) 0.119 2 (22.2) 13 (21.7) 0.970
    With cephalosporins 1 (5.88) 6 (11.5) 0.503 3 (33.3) 4 (6.7) 0.013
    With macrolides 0 (0) 5 (9.6) 0.184 0 (0) 5 (8.3) 0.369
    With quinolones 5 (29.41) 20 (38.5) 0.500 3 (33.3) 22 (36.7) 0.846
Antibiotic treatment
(8 days-2 months prior to hospitalisation):
    Yes 30 (78.9) 86 (81.1)
0.770
5 (23.8) 23 (18.7)
0.584
    No 8 (21.1) 20 (19.9)
    With penicillin + β-lactamase inhibitor 10 (33.3) 19 (22.1) 0.221 2 (12.5) 27 (27) 0.214
    With cephalosporin 3 (10) 14 (16.3) 0.402 4 (25) 13 (13) 0.208
    With macrolides 0 (0) 3 (3.5) 0.300 0 (0) 3 (3) 0.483
    With quinolones 11 (36.7) 25 (29.1) 0.439 5 (31.3) 31 (31) 0.984
Previous pneumococcal vaccinations
    Yes 23 (35.9) 80 (41.2) 13 (43.3) 90 (39.5)
    No 25 (39.1) 67 (34.5) 0.289 11 (36.7) 81 (35.5) 0.827
    Unknown 16 (25) 47 (24.2) 6 (20) 57 (25)
Comorbidities, n (%)
    CCI, median (range): 2 (2.56-3.63) 3 (2.99-3.65) 0.490 3 (2.33-3.81) 3 (2.99-3.59) 0.603
    Absence of comorbidity 13 (20.3) 46 (23.7) 7 (23.3) 52 (22.8)
    Low comorbidity 20 (31.3) 41 (21.1) 0.255 6 (20) 55 (24.1) 0.875
    High comorbidity 31 (48.4) 107 (55.2) 17 (56.7) 121 (53.1)
    Heart failure 3 (4.7) 21 (10.8) 0.481 12 (40) 53 (23.2) 0.047
    Chronic respiratory disease 27 (42.2) 76 (39.2) 0.670 20 (66.7) 83 (36.4) 0.001
    Moderate/severe chronic liver disease 2 (3.1) 0 (0) 0.013 0 (0) 19 (8.3) 0.607
CURB-65 score, n (%)
    0-1 (1.5% mortality) 24 (39.3) 58 (31) 9 (32.1) 73 (33.2)
    2 (9.2% mortality) 16 (26.2) 65 (34.8) 0.370 6 (21.4) 75 (34.1) 0.270
    ≥3 (22% mortality) 21 (34.4) 64 (34.2) 13 (46.4) 72 (32.7)
PSI class, n (%)
    I-II 5 (8.8) 16 (8.8) 4 (15.3) 17 (8)
    III 11 (19.3) 25 (13.8) 0.427 4 (15.4) 32 (15.1) 0.519
    IV-V 41 (72) 140 (77.3) 18 (69.3) 163 (76.9)
Table 1  Patient’s clinical characteristics according to the presence or absence of either 
Streptococcus pneumoniae or methicillin-resistant Staphylococcus aureus.
CCI, Charlson comorbidity index; MRSA, Methicillin-resistant Staphylococcus aureus; PSI, Pneumonia Severity Index; SD, standard deviation; S. pneumoniae, 
Streptococcus pneumoniae
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the identified serotypes included ST11A, n = 3, 21.4%; ST8, n = 
2, 14.3%; and one case each of the following: ST1, ST7F, ST6C, 
ST9N, ST10A, ST16F, ST22, ST31, ST35B (n = 1, 7.1% for each).
MRSA was identified in 30 patients (11.6%), six of which 
were isolated from normally sterile fluid samples such as blood 
or pleural fluid, or from the corresponding respiratory sample 
and nasopharyngeal exudates in the remaining 24.
Clinical data according to the presence or absence of ei-
ther S. pneumoniae or MRSA are shown in Table 1. As observed 
among the patients with significant medical histories, malig-
nancy and previous chemotherapy (in the last 30 days) were 
more frequent in patients in whom MRSA was not isolated, 
Previous pneumococcal vaccination was reported in 103 
of the 258 patients (39.9%), 93 (90.3%) of whom had received 
the polysaccharide vaccine (PPSV), three patients (2.9%) had 
received the conjugated vaccine (PCV), one patient (1%) had 
received both PCV + PPSV, and the type of vaccine was un-
known in six cases (5.8%).
Patient characteristics according to presence or ab-
sence of either S. pneumoniae or MRSA. Of the 258 samples 
tested by PCR for S. pneumoniae identification, 53 were positive. 
The remaining 205 negative specimens were further tested, yield-
ing one culture-positive sample and 10 BINAX-positive samples. 
As a result, 64 cases (24.9%) of S. pneumoniae were identified. 
Furthermore, the serotype was identified in 14 of these samples; 
Table 2  Hospitalisation-related events and follow-up according to the presence or absence of 
either Streptococcus pneumoniae or methicillin-resistant Staphylococcus aureus.
MRSA, Methicillin-resistant Staphylococcus aureus; SD, standard deviation; S. pneumoniae, Streptococcus pneumoniae









Treatment failure, n (%) 4 (6.3) 34 (17.5) 0.027 6 (20) 32 (14) 0.386
Length of stay, mean ± SD 9.5 ± 6.34 11.31 ± 8.92 0.291 11.03 ± 5.95 10.84 ± 8.66 0.285
Antibiogram-guided treatment, n (%)
Yes 25 (39.1) 28 (14.4)
0.000
13 (43.3) 40 (17.5)
0.001
No 39 (60.9) 166 (85.6)
With penicillin + β-lactamase inhibitor 3 (12) 10 (35.7) 0.045 4 (30.8) 9 (22.5) 0.547
With cephalosporins 10 (40) 5 (17.9) 0.074 2 (15.4) 13 (32.5) 0.234
With quinolones 1 (4) 2 (7.1) 0.201 0 (0) 0 (0) 0.398
Patient status at hospital discharge, n (%)
Cure without sequelae 54 (84.4) 151 (77.8)
0.526
20 (66.7) 185 (81.1)
Cure with sequelae 4 (6.3) 16 (8.2) 4 (13.3) 16 (7) 0.179
Death 6 (9.4) 27 (13.9) 6 (20) 27 (11.8)
Death related to pneumonia
Yes 5 (83.3) 22 (81.5) 0.915 4 (66.7) 23 (85.2) 0.287
No 1 (16.7) 5 (18.5) 2 (33.3) 4 (14.8)
Follow-up within 30 ± 7 days of discharge, n (%)
Yes 49 (76.6) 150 (77.3)
0.900
19 (63.3) 180 (78.9)
0.056
No 15 (23.4) 44 (22.7) 11 (36.7) 48 (21.1)
Radiographic resolution
Complete 17 (35.4) 57 (41) 2 (12.5) 72 (42.1)
Partial 7 (14.6) 41 (29.5) 0.021 4 (25) 44 (25.7) 0.023
Unknown 24 (50) 41 (29.5) 10 (62.5) 55 (32.2)
Resistant sequelae
Yes 47 (97.9) 126 (90.6) 14 (87.5) 159 (93)
No 1 (2.1) 12 (8.6) 0.253 2 (12.5) 11 (6.4) 0.648
Unknown 0 (0) 1 (0.7) 0 (0) 1 (0.6)












Age, mean ± SD 72.57 ± 11.60 70.63 ± 13.15 73.93 ± 17.03 72.19 ± 15.58 72.40 ± 15.15 0.780
Sex, n (%)
Male 24 (68.6) 7 (87.5) 19 (63.3) 19 (63.3) 170 (65.9) 0.522
Female 11 (31.4) 1 (12.5) 11 (36.7) 11 (36.7) 88 (34.1)
Patient-related factors, n (%)
Hospitalisation (previous 2 months) 17 (48.6) 5 (62.5) 19 (63.3) 84 (45.4) 125 (48.4) 0.266
Malignancy 17 (48.6) 4 (50) 9 (30) 63 (34.1) 93 (36) 0.290
COPD 12 (34.3) 3 (37.5) 16 (53.3) 48 (25.9) 79 (30.6) <0.05
Previous pneumonia 8 (22.9) 2 (25.0) 10 (33.3) 56 (30.3) 76 (29.5) 0.772
Diabetes 7 (20) 1 (12.5) 8 (26.7) 55 (29.7) 71 (27.5) 0.462
Institutionalised patients 9 (25.7) 2 (25) 11 (36.7) 48 (25.9) 70 (27.1) 0.686
Heart failure 7 (20) 1 (12.5) 10 (33.3) 47 (25.4) 65 (25.2) 0.510
Previous antibiotic treatment 21 (60) 7 (87.5) 21 (70) 95 (51.4) 144 (55.8) <0.05
Antibiotic treatment (7 days prior to hospital admission):
Yes 9 (42.9) 2 (28.6) 8 (38.1) 50 (52.6) 69 (47.9) 0.396
With penicillins 3 (33.3) 1 (50) 0 (0) 5 (10) 15 (21.7) 0.149
With cephalosporins 0 (0) 1 (50) 0 (0) 6 (12) 7 (10.1) 0.120
With macrolides 0 (0) 0 (0) 1 (12.5) 4 (8) 5 (7.2) 0.579
With quinolones 2 (22.2) 1 (50) 5 (62.5) 17 (34) 25 (36.2) 0.340
Antibiotic treatment
(8 days-2 months prior to hospitalisation):
Yes 16 (76.2) 6 (85.7) 18 (85.7) 76 (80) 116 (80.6) 0.055
With aminopenicillins 7 (43.8) 1 (16.7) 3 (16.7) 18 (23.7) 29 (25) 0.296
With cephalosporins 1 (6.3) 1 (16.7) 4 (22.2) 11 (14.5) 17 (14.7) 0.745
With macrolides 0 (0) 0 (0) 1 (5.6) 2 (2.6) 3 (2.6) 0.467
With quinolones 6 (37.5) 3 (50) 7 (38.9) 20 (26.3) 36 (31) 0.267
Previous pneumococcal vaccinations
0.951
Yes 14 (40) 2 (25) 12 (40) 75 (40.5) 103 (39.9)
No 13 (37.1) 4 (50) 12 (40) 63 (34.1) 92 (35.7)
Unknown 8 (22.9) 2 (25) 6 (20) 47 (25.4) 63 (24.4)
Current inhaled corticosteroid treatment, n (%)
Yes 12 (34.3) 2 (25) 13 (43.3) 32 (17.3) 59 (22.9)
<0.01
No 23 (65.7) 6 (75) 17 (56.7) 153 (82.7) 199 (77.1)
Comorbidities, n (%)
CCI, median (range): 2 (2.44-4.01) 3.5 (1.48-5.77) 3 (2.91-3.59) 3 (2.91-3.59) 3 (2.99-3.54) 0.973
Absence of comorbidity 6 (17.1) 2 (25) 5 (16.7) 46 (24.9) 59 (22.9)
Low comorbidity 13 (37.1) 0 (0) 6 (20) 42 (22.7) 61 (23.6) 0.955
High comorbidity 16 (45.7) 6 (75) 19 (63.3) 97 (52.4) 138 (53.5)
Chronic respiratory disease 17 (48.6) 4 (50) 18 (60) 64 (34.6) 103 (39.9) <0.05
Lymphoma 6 (17.1) 0 (0) 0 (0) 13 (7) 19 (7.4) <0.05
CURB-65 score, n (%)
0-1 14 (41.2) 3 (50) 9 (31) 56 (31.3) 82 (33.1)
2 10 (29.4) 3 (50) 9 (31) 59 (33) 81 (32.7) 0.371
≥3 10 (29.4) 0 (0) 11 (37.9) 64 (35.8) 85 (34.3)
PSI class, n (%)
I-II 2 (6.3) 0 (0) 3 (10.3) 16 (9.5) 21 (8.8)
III 6 (18.8) 3 (37.5) 3 (10.3) 24 (4.2) 36 (15.1) 0.691
IV-V 24 (75) 5 (62.5) 23 (79.3) 129 (76.3) 181 (76.1)
Presentation of pneumonia at hospital admission
Non-complicated pneumonia 14 (40) 3 (37.5) 6 (20) 86 (46.5) 109 (42.2)
0.043
Complicated pneumonia 21 (60) 5 (62.5) 24 (80) 99 (53.5) 149 (57.8)
Presentation of pneumonia at hospital admission (patients with COPD)
Non-complicated pneumonia 5 (41.7) 1 (33.3) 2 (12.5) 24 (50) 32 (40.5)
0.043
Complicated pneumonia 7 (58.3) 2 (66.7) 14 (87.5) 24 (50) 47 (59.5)
Table 3  Patient’s clinical characteristics according to causative pathogen
CCI, Charlson Comorbidity Index; COPD, Chronic Obstructive Pulmonary Disease; MRSA, Methicillin-resistant Staphylococcus aureus; PSI, Pneumonia Severity Index; S. pneumoniae, 
Streptococcus pneumoniae;
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23.2% , p < 0.05; n = 20; 66.7% vs. n = 83; 36.4% , p = 0.001 
respectively), and the incidence of moderate/severe chronic 
liver disease in the S. pneumoniae-positive group (n = 2; 3.1% 
vs. n = 0; 0% , p < 0.05).
No significant differences in CURB-65 and PSI scores were 
reported between the groups.
Outcomes according to the presence or absence of ei-
ther S. pneumoniae or MRSA. Relevant data are presented in 
Table 2. Treatment failure rates were higher in patients not in-
fected or colonised by S. pneumoniae (n = 34; 17.5% vs. n = 4; 
6.3%, p < 0.05). There were no differences in the mean length 
of stay (LOS) among the groups. Treatment was guided by an-
tibiogram significantly more often in groups in which either S. 
pneumoniae or MRSA were identified (p < 0.001 and p = 0.001, 
respectively). Treatment with a penicillin plus a β-lactamase 
inhibitor was more common in the group in which S. pneumo-
niae was not identified (n = 10; 35.7% vs. n = 3; 12%, p < 0.05). 
Although death was more frequently reported in the ab-
sence of either S. pneumoniae (n = 27; 13.9% vs. n = 6; 9.4%) 
or MRSA (n = 27; 11.8% vs. n = 6; 20%), the differences were 
not statistically significant. 
while institutionalisation and COPD were more common in the 
MRSA-positive patient group. No differences in any comorbid-
ities were detected according to the presence or absence of S. 
pneumoniae. No differences were observed in previous antibi-
otic treatment, regardless of the presence or absence of either 
S. pneumoniae or MRSA. However, treatment with cephalo-
sporins seven days prior to hospital admission was significantly 
more frequent in patients with MRSA (n = 3; 33.3% vs. n = 
4; 6.7%, p < 0.05). Previous pneumococcal vaccination was 
reported in 23 patients (35.9%) in the S. pneumoniae group; 
of these, 22 (95.7%) had received the polysaccharide vaccine 
(PPSV). In the MRSA group, 13 patients (43.3%) had previously 
received pneumococcal vaccination; of these, 12 (92.3%) had 
received PPSV and only one patient had received the conjugat-
ed vaccine (7.7%).
CCI score was also calculated, and no differences were 
found between the groups colonised or infected with either S. 
pneumoniae or MRSA and their respective control groups. In-
terestingly, specific comorbidities were significantly more fre-
quent in groups that were positive for any of the pathogens, 
including the incidence of heart failure and chronic respiratory 












Treatment failure, n (%) 3 (8.6) 2 (25) 4 (13.3) 29 (15.7) 38 (14.7) 0.576
Length of stay (days), mean ± SD 9.57 ± 6.77 22.13 ± 16.31 13.17 ± 10.61 10.24 ± 7.39 10.86 ± 8.38 0.005
Patient status at hospital discharge, n (%)
Cure without sequelae 30 (85.7) 3 (37.5) 26 (86.7) 146 (78.9) 205 (79.5)
Cure with sequelae 2 (5.7) 3 (37.5) 3 (10) 12 (6.5) 20 (7.8) 0.047
Death 3 (8.6) 2 (25) 1 (3.3) 27 (14.6) 33 (12.8)
Death related to pneumonia
0.034Yes 3 (100) 0 (0) 1 (100) 23 (85.2) 27 (81.2)
No 0 (0) 2 (100) 0 (0) 4 (14.8) 6 (18.2)
Follow-up within 30 ± 7 days of discharge, n (%)
Yes 29 (82.9) 4 (50) 28 (93.3) 138 (74.6) 199 (77.1) 0.020
No 6 (17.1) 4 (50) 2 (6.7) 47 (25.4) 59 (22.9)
Radiographic resolution
Complete 15 (51.7) 1 (25) 9 (36) 49 (38) 74 (39.6)
Partial 4 (13.8) 1 (25) 4 (16) 39 (30.2) 48 (25.7) 0.315
Unknown 10 (34.5) 2 (50) 12 (48) 41 (31.8) 65 (34.8)
Resistant sequelae
Yes 1 (3.4) 1 (25) 3 (12) 173 (92.5) 13 (7)
No 28 (96.6) 3 (75) 22 (88) 120 (93) 48 (25.7) 0.731
Unknown 10 (34.5) 2 (50) 12 (48) 41 (31.8) 65 (34.8)
Table 4  Hospitalisation-related events and follow-up according to pneumonia-causing pathogen
MRSA, Methicillin-resistant Staphylococcus aureus; SD, standard deviation; S. pneumoniae, Streptococcus pneumoniae
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absence of two of the most relevant pathogens implicated in 
the disease, S. pneumoniae and MRSA. 
Our results show that S. pneumoniae is the most frequent 
causative agent of pneumonia identified in our population, 
confirming the results of previous studies conducted in Spain 
[6, 19, 29], United Kingdom [30] and Japan [4]. However, it is 
interesting to observe that the etiology of pneumonia could 
not be determined in most patients, something that under-
lines two diagnostic-related issues widely discussed in the lit-
erature: the lack of sensitivity of conventional cultured-based 
methods and the difficulty of obtaining good quality speci-
mens from the lower respiratory tract [31, 32]. Taking into ac-
count these problems, we performed an analysis based on the 
causative agent, and also included patients in whom etiology 
could not be determined. 
In our series, a previous history of COPD was the third 
most frequent clinical characteristic reported. COPD also 
showed significant differences when pneumonia was classi-
fied according to etiology, being most common in the “Others” 
group. Interestingly, chronic respiratory diseases identified at 
presentation was the comorbidity that was also most frequent 
in patients with pneumonia due to causative agents oth-
er than MRSA or S. pneumoniae. Our results confirmed that, 
on the one hand, COPD is common in HCAP patients. Indeed, 
previous studies have demonstrated that its incidence as a co-
morbid condition is comparable to [19] or even higher than in 
CAP patients [29], in whom COPD can also be considered as the 
most frequent comorbidity associated with the development 
of pneumonia [33]. In view of the available data, it is tempting 
to think that this might also be the case in HCAP patients. On 
the other hand, although S. pneumoniae is one of the most 
frequently identified pathogens both in stable periods and in 
exacerbations in COPD, our results suggest that HCAP patients 
with this pathology may be exposed to a greater potential risk 
of presenting colonisation or infections by other microorgan-
isms.
Another important factor was prior use of antibiotics, and 
indeed, this is one of the criteria that may define an HCAP pa-
tient [3]. Interestingly, we found significant differences among 
the analysed groups, with the MRSA group accounting for a 
higher proportion of patients who had received previous an-
tibiotic treatment. These results are not surprising consider-
ing that prior antibiotic use (particularly cephalosporins and 
quinolones) is considered one of the major risks for health-
care-associated MRSA infections [34]. 
Besides these cases of prior antibiotic use, common caus-
ative agents such as S. pneumoniae and known risk factors for 
pneumococcal disease, which include many of the comorbid-
ities already mentioned [35], must be taken into account, and 
the importance of a preventive approach by vaccination for 
patients with these conditions must be emphasised. In fact, 
our data also show that, in the S. pneumoniae group, only 
around one-third of patients had received previous pneumo-
coccal vaccinations despite their baseline risk conditions. This 
highlights the need for including pneumococcal vaccination 
Patient characteristics according to causative agent. 
The etiology of pneumonia was identified in 73 of the 258 
patients (28.3%). S. pneumoniae was identified in 35 cases 
(13.6%), MRSA in 8 (3.1%), and other microorganisms were 
identified in 30 cases (11.6%). In the latter group, the most 
common microorganisms were Escherichia coli (n = 5, 16.7%), 
followed by Klebsiella pneumoniae (n = 4, 13.3%) and Haemo-
philus influenzae (n = 3, 10%). 
Clinical data are shown in Table 3. Among patient-related 
factors, the incidence of chronic obstructive pulmonary dis-
ease (COPD) (n = 79; 30.6%) differed significantly depending 
on the HCAP causative agent (p < 0.05) and was higher in the 
group of microorganisms other than S. pneumoniae and MRSA 
(“Others” group). A total of 144 patients (55.8%) had received 
previous antibiotic treatment, with a higher prevalence in the 
MRSA group (n = 7; 87.5%) compared to the other categories 
(p < 0.05). Regarding comorbidity, there was no difference in 
the CCI score among the analysed groups, with more than half 
of the patients showing high comorbidity (n = 138; 53.5%). 
However, the incidence of chronic respiratory disease and lym-
phoma was significantly higher in the “Others” and “S. pneu-
moniae” groups, respectively (p < 0.05 in both cases). 
No significant differences among groups were reported in 
comorbidity measured with the CURB-65 and PSI scores. The 
most frequent comorbidity was complicated pneumonia (n = 
149; 57.8%), that also showed differences among the groups 
(S. pneumoniae: n = 21; 60%; MRSA: n = 5; 62.5%; Others: 
n = 24; 80%; Unknown: n = 99; 53.5%. p < 0.05). Complicat-
ed pneumonia was also more common than non-complicated 
pneumonia in the 79 patients with COPD (n = 47; 59.5% and 
n = 32; 40.5% respectively), and the incidence of complicated 
pneumonia was also significantly related to the etiology of the 
episode (S. pneumoniae: n = 7; 58.3%; MRSA: n = 2; 66.7%; 
Others: n = 14; 87.5%; Unknown: n = 24; 50%. p < 0.05).
Outcomes according to HCAP causative agent. Rele-
vant data are presented in Table 4. Thirty-eight patients (14.7%) 
were treatment failures. Mean LOS was 10.86 days ± 8.38 days 
[95% CI (9.83-11.89)] and differed according to the etiology of 
pneumonia (p < 0.01), with the longest stays recorded in the 
MRSA group [22.13 days ± 16.31 days; 95% CI (8.49-35.76)] 
compared to the other categories.
Overall, 33 (12.8%) patients died during hospitalisation, 
27 (81.2%) of which were considered related to pneumonia. 
Of these cases, 3 were caused by S. pneumoniae, one by other 
microorganisms, and in 23 cases the etiology was unknown. 
These differences were statistically significant (p < 0.05).
A follow-up visit within 30 ± 7 days of discharge was suc-
cessfully performed in 199 patients (77.1%). 
DISCUSSION
Our data provides an updated overview of the epidemio-
logical status of HCAP in Spain. To our knowledge, this is the 
first study in which these patients were evaluated according to 
the etiology of pneumonia and according to the presence or 
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The concept of HCAP was firstly introduced to define 
patients at higher risk of antibiotic-resistant pathogens, who 
would thus require broad-spectrum therapy [2, 3]. However, 
over the course of this study, an intense debate on the useful-
ness of that definition in identifying these patients has sprung 
up. Thus, in recent years, several studies have concluded that 
the definition of HCAP may be sensitive but lacking in spec-
ificity and, as a consequence, it does not accurately identify 
resistant pathogens [11-14]. Indeed, three recent studies have 
proposed new methods to define patients with an increased 
risk of developing pneumonia due to multidrug-resistant bac-
teria [45-47]. 
This study has some limitations. Firstly, our sample size 
was limited, preventing us from making predictions and asso-
ciation analysis. Secondly, microbiological and serotype data 
on S. pneumoniae were also limited, and the impact of cer-
tain serotypes on HCAP could not be evaluated. Nevertheless, 
this multicentre prospective study is the first to evaluate HCAP 
patients according to the etiology of their pneumonia, thus 
helping identify risks and prognostic factors that might help 
to guide treatment in these patients, with enough statistical 
power.
Therefore, despite the limitations, the results show that 
the etiology of patients with HCAP is still unknown in most 
cases, although S. pneumoniae appears as the most prevalent 
microorganism. In patients with COPD, however, a major pro-
portion of HCAP caused by other microorganisms other than 
S. pneumoniae and MRSA was observed. Importantly, death in 
the overall population within the first month after discharge 
was related in most of the cases to pneumonia. Our study of-
fers an updated view of the characteristics and outcomes of 
these patients in the Spanish population, but further research 
is needed to provide data to help identifying predictive factors 
for HCAP to improve prevention and management strategies.
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as part of routine recommendations for the management of 
these patients. Although serotype information is limited in 
this study due to the low numbers, it is interesting to note the 
presence in HCAP of some of the serotypes most frequent-
ly found in CAP cases (1 or 7F, and in the last few years also 
8), and the absence of others usually very common in CAP in 
adults such as serotype 3, as observed in previous studies in 
Spain [36]. 
In terms of the risk of mortality, neither CURB-65 nor PSI 
scores were significantly different according to the etiology of 
pneumonia, in line with the results suggested in the study by 
Polverino et al [19]. In this Spanish study, no differences were 
reported between the agents causing pneumonia when HCAP 
and CAP patients were compared. However, increased mortal-
ity was reported in the former group, which led the authors 
to conclude that the microbiological etiology could not be the 
principal cause of the difference. 
Clinical outcomes in HCAP patients seem to be worse than 
in CAP patients [6, 19, 29]. As such, they require longer hos-
pital stays [6] and, as our results suggest, this time depends 
on the microorganism identified as causative agent. Specifi-
cally, patients with MRSA pneumonia showed the longest LOS, 
underlining the problems that this pathology represents in 
terms of management and costs, as discussed by other authors 
[37]. Although it was not possible to evaluate the influence of 
treatment on outcomes, the etiology of pneumonia appears 
to be an important factor when evaluating the outcomes and 
treatment required by these patients. On the other hand, pa-
tients’ status at hospital discharge also differed according to 
the causative agent and, although death related to pneumonia 
was not frequent, it was identified as the cause of death in the 
two patients with MRSA pneumonia who died. This stresses 
the need for a special focus on resistant pathogens, that, spe-
cifically in the case of MRSA, are the cause of increased mor-
tality and morbidity rates [38, 39]. In line with this, an overall 
mortality rate of 17.8% was reported at the end of the study, 
which is within the range of previous estimates for HCAP pa-
tients in Spain [19, 29].
From our analysis of cases according to the presence or 
absence of S. pneumoniae or MRSA, our results were particu-
larly relevant in the case of MRSA. First, despite S. pneumoni-
ae being the most frequent pathogen reported, we were still 
able to detect 11.6% cases positive for MRSA, which not on-
ly confirms the results obtained by Polverino et al. [19], but 
also highlights the growing problem of antibiotic resistance. 
Our data allows us to envisage a MRSA-positive patient profile 
in which COPD and previous institutionalisation are frequent 
underlying factors. Indeed, both have been previously recog-
nised as risk factors for MRSA infection [40-43]. Furthermore, 
heart failure and chronic respiratory diseases were especially 
frequent in these patients. This illustrates a common problem 
in clinical practice in the form of delayed resolution of pneu-
monia, which is often affected by underlying COPD [44], a 
comorbidity or underlying factor that we also detected in our 
population.
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